---
title: "Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash Runway"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286291566.md"
description: "H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Assembly Biosciences, maintaining a price target of $50. The rating is based on the company's progress in its pipeline, including advancements in its herpes and hepatitis delta virus programs. Trucchio notes the completion of chronic toxicology work for ABI-6250 and highlights the importance of a mid-2026 decision regarding the HSV program. With a strong cash position extending into 2028, he believes the company is well-positioned for upcoming catalysts. Guggenheim also maintains a Buy rating with a $43 price target."
datetime: "2026-05-13T16:06:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286291566.md)
  - [en](https://longbridge.com/en/news/286291566.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286291566.md)
---

# Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash Runway

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Assembly Biosciences today and set a price target of $50.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Patrick Trucchio has given his Buy rating due to a combination of factors tied to Assembly Biosciences’ execution and pipeline visibility. He highlights that first-quarter 2026 results demonstrated continued progress in both the partnered recurrent genital herpes program and the in-house hepatitis delta virus candidate, with Phase 1b follow-up for ABI-5366 and ABI-1179 confirming earlier safety and efficacy observations under Gilead’s stewardship.

Trucchio also points to the completion of chronic toxicology work for ABI-6250, which underpins planned Phase 2 dosing and supports a late-2026 trial start in chronic HDV, alongside upcoming data at EASL that should maintain scientific momentum. He views the mid-2026 decision on whether to take a 40% U.S. cost and profit share in the HSV program as a key valuation inflection point, while the strong cash position, extending into 2028, provides sufficient runway to reach multiple catalysts; accordingly, he reiterates a Buy rating with an unchanged $50 price target.

In another report released on May 10, Guggenheim also reiterated a Buy rating on the stock with a $43.00 price target.

### Related Stocks

- [ASMB.US](https://longbridge.com/en/quote/ASMB.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)

## Related News & Research

- [Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference](https://longbridge.com/en/news/286404799.md)
- [Assembly Biosciences GAAP EPS of -$0.54 beats by $0.03, revenue of $8.21M beats by $1.26M](https://longbridge.com/en/news/285623777.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [Do Wall Street Analysts Like Equity Residential Stock?](https://longbridge.com/en/news/286806057.md)
- [Core Scientific Is Firing on All Cylinders as Analysts Approve Its Expansion Plans](https://longbridge.com/en/news/286808678.md)